Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.
Kruszewski
Stefan P
SP
Shane
John A
JA
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards; D000700:Analgesics / Q000009:adverse effects*; D014151:Anti-Anxiety Agents / Q000009:adverse effects; D001835:Body Weight / Q000187:drug effects; D016265:Conflict of Interest; D018849:Controlled Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D018755:GABA Agonists / Q000009:adverse effects; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D015990:Placebo Effect; D000069583:Pregabalin; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards; D013119:Spinal Cord Injuries / Q000150:complications* / Q000503:physiopathology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives*
D000700:Analgesics; D014151:Anti-Anxiety Agents; D018755:GABA Agonists; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid